Status:
UNKNOWN
Vaccine Therapy in Treating Patients With Malignant Melanoma
Lead Sponsor:
CancerVax Corporation
Conditions:
Melanoma (Skin)
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy to see how well it works i...
Detailed Description
OBJECTIVES: * Determine the response in patients with in-transit cutaneous malignant melanoma treated with active immunotherapy comprising polyvalent melanoma vaccine (Canvaxin™). OUTLINE: This is a...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed malignant melanoma
- At least 1 in-transit skin lesion measuring 3-10 mm in the longest diameter
- PATIENT CHARACTERISTICS:
- Age
- 18 to 80
- Performance status
- Not specified
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Not specified
- Chemotherapy
- Not specified
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- Not specified
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00128583
Start Date
July 1 2005
Last Update
December 19 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Comprehensive Cancer Center at Desert Regional Medical Center
Palm Springs, California, United States, 92262
2
John Wayne Cancer Institute at Saint John's Health Center
Santa Monica, California, United States, 90404
3
Lakeland Regional Cancer Center at Lakeland Regional Medical Center
Lakeland, Florida, United States, 33804-1057
4
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
Tampa, Florida, United States, 33612-9497